Neofit Spasov

Neofit Spasov

Auto-generated profile, based on publicly available information

Neofit Spasov

Medical University of Plovdiv, Plovdiv, Bulgaria

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in The Journal of Pathology
Verified
Journal Article
Open access
NKNatálie Klubíčková
Natálie Klubíčková
JDJosephine K Dermawan
Josephine K Dermawan
EMElaheh Mosaieby
Elaheh Mosaieby
PMPetr Martínek
Petr Martínek
TVTomáš Vaněček
Tomáš Vaněček
MMMichael Michal
Michael Michal
Alterations in kinase genes such as NTRK1/2/3 , RET , and BRAF underlie infantile fibrosarcoma (IFS), the emerging entity ‘ NTRK ‐rearranged spindle cell neoplasms’ included in the latest WHO classification, and a growing set of tumors with overlapping clinical and pathological features. In this study, we conducted a comprehensive clinicopathological and molecular analysis of 22 cases of IFS and other kinase gene‐altered spindle cell neoplasms affecting both pediatric and adult patients. Follow‐up periods for 16 patients ranged in length from 10 to 130 months (mean 38 months). Six patients were treated with targeted therapy, achieving a partial or complete response in five cases. Overall, three cases recurred and one metastasized. Eight patients were free of disease, five were alive with disease, and two patients died. All cases showed previously reported morphological patterns. Based on the cellularity and level of atypia, cases were divided into three morphological grade groups. S100 protein and CD34 were at least focally positive in 12/22 and 14/22 cases, respectively. Novel PWWP2A::RET , NUMA1::RET , ITSN1::RAF1 , and CAPZA2::MET fusions, which we report herein in mesenchymal tumors for the first time, were detected by RNA sequencing. Additionally, the first uterine case with BRAF and EGFR mutations and CD34 and S100 co‐expression is described. DNA sequencing performed in 13 cases uncovered very rare additional genetic aberrations. The CNV profiles showed that high‐grade tumors demonstrate a significantly higher percentage of copy number gains and losses across the genome compared with low‐ and intermediate‐grade tumors. Unsupervised clustering of the tumors’ methylation profiles revealed that in 8/9 cases, the methylation profiles clustered with the IFS methylation class, irrespective of their clinicopathological or molecular features. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

27 May 2022 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Open access
NSNeofit J. Spasov
Neofit J. Spasov
FDFrank Dombrowski
Frank Dombrowski
Holger N. LodeHolger N. Lode
Holger N. Lode
MSMariya Spasova
Mariya Spasova
LILiliya Ivanova
Liliya Ivanova
NSNikolai Siebert
Nikolai Siebert
Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation.

1 January 2021 in Case Reports in Pediatrics
Verified
Journal Article
Open access
PDF file
NSNeofit Spasov
Neofit Spasov
MSMariya Spasova
Mariya Spasova
Neuroblastoma is the most common extracranial solid tumor in children, accounting for 15% of all pediatric cancer deaths. High‐risk neuroblastoma (HRNB) is a particularly difficult‐to‐treat form of the disease that requires aggressive multimodality therapy, including induction chemotherapy, consolidation therapy with high‐dose chemotherapy and autologous stem cell transplant, and maintenance therapy with dinutuximab beta. Despite treatment advances, the prognosis of these patients remains poor. As a better response to induction therapy has been associated with prolonged survival in patients with HRNB, we hypothesized that early use of dinutuximab beta—post‐induction chemotherapy—may improve patient outcomes. We describe here our experience of administering at least one cycle of dinutuximab beta post‐induction and prior to surgery in three children with HRNB who did not demonstrate a complete response to induction chemotherapy. All three patients achieved complete remission. Early use of dinutuximab beta may therefore have the potential to improve outcomes in patients with HRNB.

31 December 2020 in Folia Medica
Verified
Journal Article
Open access
NSNeofit Spasov
Neofit Spasov
DDDiana Dimitrova-Popova
Diana Dimitrova-Popova
NTNikoleta Traikova-Djambazova
Nikoleta Traikova-Djambazova
MSMariya Spasova
Mariya Spasova
MBMiroslava Bosheva
Miroslava Bosheva
Introduction: Blood-induced joint damage as a hallmark of haemophilia continues to occur despite the widespread prophylaxis. Pre-cise assessment and follow-up of joint status are crucial for tailoring their treatment. Aim: To study the correlation between the bleeding phenotype, the functional joint status, and the magnetic resonance imaging score in pediatric patients with haemophilia. Materials and methods: Eighty-six joints (ankles, knees, and elbows) in patients aged 10.7±0.5 (range 4 - 20) years with severe/moderate haemophilia A, severe haemophilia B and haemophilia A with inhibitors were included in the study. The joints were assessed by Haemophilia Joint Health Score 2.1 (HJHS2.1) one month after the last hemarthrosis in a non-bleeding state. The magnetic reso-nance imaging was performed on 40 (46.5%) of the examined hemophilic joints (16 ankles, 11 knees and 13 elbows). Results: Joint bleeds were present in 37 (38.9%) of the joints with ankles being the most commonly affected. Sixty joints (69.8%) had normal HJHS2.1 score. Only the loss of flexion score differed significantly between the joints and the ankles had highest score. The cumulative number of hemarthrosis in the joint correlated moderately with hemosiderin deposition and strongly with the formation of subchondral cysts on magnetic resonance imaging. The magnetic resonance imaging scores for soft tissue and osteochondral domains correlated moderately with the cumulative number of hemarthrosis in the joint and only with the presence of pain and crepitus of mo-tion from the physical examination. Conclusions: Magnetic resonance imaging is more sensitive than the bleeding phenotype and physical examination in detecting early signs of haemophilic arthropathy.

1 June 2018 in Folia Medica
Verified
Journal Article
Open access
PDF file
HBHasan Burnusuzov
Hasan Burnusuzov
MYMaya N. Yordanova
Maya N. Yordanova
BABoryana E. Avramova
Boryana E. Avramova
NYNadezhda N. Yurukova
Nadezhda N. Yurukova
KBKonstantin N. Bachvarov
Konstantin N. Bachvarov
DKDobrin N. Konstantinov
Dobrin N. Konstantinov
Background: During the last four decades the prognosis of childhood acute myeloid leukemia (AML) has been substantially improved due to an increase in complete remission (CR) rates, event-free survival (EFS) and reduced early mortality. The relapsed AML still remains a therapeutic challenge. Aim: To report the AML treatment results of the Bulgarian pediatric oncohematological centers. Materials and methods: Retrospective analysis of the treatment results of children and adolescents (age from 0 to 20 years) with primary AML. Unified AML BFM- backbone type treatment protocol is used. Results: This study included 97 newly diagnosed patients (44 girls and 53 boys) with AML in Bulgaria between 2003 and 2016. The median age at diagnosis was 10.2 years. The most frequent FAB-morphologic subtype was M2 followed by M4. First complete remission (CR1) was achieved in 83 patients (85.6%). The 13-year EFS was 49%, while the overall survival (OS) was 54.6%. Twenty seven (27.8%) patients relapsed, with only 5 of them being still alive towards the end of the study period. Conclusion: The EFS and OS for the children with AML in Bulgaria are comparable with those reported by other European groups. The prognosis of relapsed AML remains still unfavorable for the past 13 years.

30 October 2025 in Folia Medica
Verified
Journal Article
Open access
PMPETYA Petkova MARKOVA
PETYA Petkova MARKOVA
MSMariya Spasova
Mariya Spasova
NSNeofit Spasov
Neofit Spasov
SMStoyan Markov
Stoyan Markov
Methotrexate, administered in high doses, is utilized in the treatment of a range of childhood cancers. Despite the implementation of routine supportive measures, including intensive hydration, urine alkalinization, and antidote therapy, nephrotoxicity remains a significant problem. The literature suggests a range of frequencies from 1.8% to 36%, depending on the diagnostic method employed. The primary pathogenetic mechanism of its occurrence is the precipitation of methotrexate and its metabolites in the renal tubules, clinically manifesting as crystalline nephropathy, which leads to delayed excretion of the medication. The risk factors, long-term renal prognosis, and safety of re-administration of high-dose methotrexate after an episode of acute kidney injury remain unclear. In the event of nephrotoxicity, restriction of its further use and substitution with another cytostatic drug are often considered. The following clinical case is presented: a 13-year-old girl with osteosarcoma was administered high-dose methotrexate, resulting in fourth-degree acute kidney injury. This necessitated a renal replacement therapy. Given its pivotal role in osteosarcoma treatment, subsequent courses were planned with gradually increasing doses. Four additional courses of high-dose methotrexate were administered at doses of 3 g/m 2 , 8 g/m 2 , and 12 g/m 2 , until the maximum tolerable dose of 20 grams was reached. These courses were well tolerated, with no evidence of toxicity, and the medication was eliminated in a timely manner.